164 related articles for article (PubMed ID: 32308757)
1. Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with
von Eyben FE; Kulkarni HR; Baum RP
Theranostics; 2020; 10(11):4900-4902. PubMed ID: 32308757
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
4. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
6. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
7. Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
Seifert R; Kessel K; Boegemann M; Köhler M; Roll W; Stegger L; Weckesser M; Rahbar K
J Nucl Med; 2020 May; 61(5):723-728. PubMed ID: 31601703
[TBL] [Abstract][Full Text] [Related]
8. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
[TBL] [Abstract][Full Text] [Related]
9. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
Ahmadzadehfar H; Rahbar K; Baum RP; Seifert R; Kessel K; Bögemann M; Kulkarni HR; Zhang J; Gerke C; Fimmers R; Kratochwil C; Rathke H; Ilhan H; Maffey-Steffan J; Sathekge M; Kabasakal L; Garcia-Perez FO; Kairemo K; Maharaj M; Paez D; Virgolini I
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):113-122. PubMed ID: 32383093
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
11. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
12. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
13. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
[TBL] [Abstract][Full Text] [Related]
15. The value of tumor markers in men with metastatic prostate cancer undergoing [
Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
[TBL] [Abstract][Full Text] [Related]
16. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
17.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
Mehrens D; Kramer KKM; Unterrainer LM; Beyer L; Bartenstein P; Froelich MF; Tollens F; Ricke J; Rübenthaler J; Schmidt-Hegemann NS; Herlemann A; Unterrainer M; Kunz WG
J Natl Compr Canc Netw; 2023 Jan; 21(1):43-50.e2. PubMed ID: 36634610
[TBL] [Abstract][Full Text] [Related]
19. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
[TBL] [Abstract][Full Text] [Related]
20. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U
J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
